Financial GrowthAnalyst maintains an Outperform rating with a $49 price target, underpinned by the company's potential to return to mid- to high-single-digit growth in the near future.
Market ValuationQGEN's stock presents a potential valuation upside, currently trading at a discount compared to historical averages, which may attract more investor interest.
Product PerformanceQuantiFERON continues to display solid momentum, driven by double-digit growth across all regions, enhancing the platform's competitive positioning.